Aclarion, Inc. (NASDAQ:ACON – Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 471,200 shares, an increase of 90.7% from the February 13th total of 247,100 shares. Approximately 93.3% of the shares of the stock are short sold. Based on an average daily volume of 3,450,000 shares, the short-interest ratio is presently 0.1 days.
Wall Street Analyst Weigh In
ACON has been the subject of several analyst reports. Maxim Group reissued a “hold” rating on shares of Aclarion in a report on Friday, December 13th. Ascendiant Capital Markets dropped their price objective on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating for the company in a report on Wednesday, November 27th.
Read Our Latest Stock Analysis on ACON
Aclarion Stock Up 12.7 %
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Featured Stories
- Five stocks we like better than Aclarion
- How to Start Investing in Real Estate
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- P/E Ratio Calculation: How to Assess Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What is diluted earnings per share (Diluted EPS)?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
